AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02839798 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEST (NeoSync EEG Synchronized TMS)
Description: The NeoSync EEG Synchronized TMS (NEST) is an electromechanical medical device that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of Bipolar Depression.
Study NCT02642237 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluenz
Description: intranasal inoculation with Fluenz
Study NCT02642237 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Fluenz
Description: intranasal inoculation with Fluenz
Study NCT02642237 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02642237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LPS
Study NCT01416116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QUTENZA
Description: topical
Study NCT01416116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: topical
Study NCT01416116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: oral
Study NCT01955512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 75mg daily for 7 days
Study NCT01955512 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study NCT00136760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Contingent reinforcement plus bupropion (300 mg/day for 3 weeks)
Study NCT00136760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contingent reinforcement plus placebo
Description: contingent reinforcement plus placebo (3 weeks)
Study NCT00136760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: non-contingent reinforcement plus bupropion
Description: non-contingent reinforcement plus bupropion (300 mg/day for 3 weeks)
Study NCT00136760 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non-contingent reinforcement plus placebo
Description: Non-contingent reinforcement plus placebo
Study NCT02388698 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical swab
Description: Cervical Swab at baseline.~HPV testing at recurrence, if applicable.
Study NCT02388698 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET-CT
Description: PET-CT will be completed 3 month post chemoradiation.
Study NCT02388698 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma HPV
Description: Plasma HPV will be drawn at baseline, post radiation, 3 month post chemoradiation and at progression (if necessary).
Study NCT02773069 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Church Bridge Project
Description: Community-based participatory research combining efforts of academic researchers, church leaders, primary care providers and community stakeholders.
Study NCT02731508 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Bihemispheric transcranial direct current stimulation
Description: 5x5 cm tDCS electrode over C3 or C4 (10-20 system) with concurrent rehabilitation
Study NCT02731508 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bihemispheric transcranial direct current stimulation
Description: 5x5 cm tDCS electrode over C3 or C4 (10-20 system) with concurrent rehabilitation
Study NCT04095988 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic microbiota reconstitution
Description: gastroscopic microbiota Infusion (Verum)
Study NCT04095988 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Allogeneic microbiota reconstitution
Description: gastroscopic saline Infusion (placebo)
Study NCT03011840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information leaflet
Description: Patient information leaflet with instructions to be carried out before procedure under general anesthesia
Study NCT04210596 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soft tissue augmentation at the buccal aspect of single implants
Description: Soft tissue augmentation is performed following mucoperiosteal flap elevation at the buccal aspect of single implants. The connective tissue graft (control) or collagen matrix (test) is inserted in the buccal pouch and attached with monofilament sutures.
Study NCT04210596 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Soft tissue augmentation at the buccal aspect of single implants
Description: Soft tissue augmentation is performed following mucoperiosteal flap elevation at the buccal aspect of single implants. The connective tissue graft (control) or collagen matrix (test) is inserted in the buccal pouch and attached with monofilament sutures.
Study NCT04467606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a discharge planning using the strategy of motivational interviewing
Description: The experimental group will receive a discharge planning which use the strategy of motivational interviewing. The discharge planning will be provided individually at the following time points: before discharge, on post-discharge days 3, 7, 14, 21, 28, and then each month till one year.
Study NCT02122172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afatinib dimaleate
Description: Given PO
Study NCT02122172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03165513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mhGAP-IG
Description: psychosocial interventions
Study NCT04461405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INTEGRATE-D
Description: INTEGRATE-D provides primary care practices with evidence-based training and support which includes: (1) Electronic health record (EHR)-based support-to help align EHR use with ADA recommendations and enable screening for depression, anxiety, DM distress, cognitive impairment, and self-management, and support identifying and tracking progress on patient treatments and goals; (2) Audit and feedback which involves assisting practices in accessing clinically relevant, actionable data reports to inform measurement and identification of care gaps in DMII and behavioral health care; (3) Skill-building resources including training on ADA-recommended care; and (4) Facilitation-to help implement the above strategies and the practice changes needed to align care with ADA recommendations.
Study NCT03241758 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Doppler ultrasound
Description: Basal Doppler ultrasound and Doppler ultrasound one year after radical prostatectomy
Study NCT00390000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vatalanib
Description: Given orally
Study NCT00390000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Given IV
Study NCT00390000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative study
Study NCT00390000 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound imaging
Description: Correlative study
Study NCT03063775 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BioOss® + Mucograft Seal®
Description: Placement of BioOss®-Collagen into the extraction socket. The Mucograft Seal® Membrane is then applied to the socket.
Study NCT03063775 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FGG + Bio-Oss®
Description: Placement of BioOss®-Collagen into the extraction socket. The FGG is then attached to the socket.
Study NCT03063775 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FGG + Gelatine sponge (Spongostan®)
Description: Placement of a Gelatine sponge into the extraction socket, then attaching the FGG to the socket.
Study NCT00233987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: 150 mg/m\^2 IV over 2 hours 4, 5, and 6 days before transplant.
Study NCT00233987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 100 mg/kg IV 2 days before transplant.
Study NCT03063775 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spongostan®+ Mucograft® Seal
Description: Placement of a Gelatine sponge into the extraction socket, then attaching the Mucograft® Seal Membrane to the socket
Study NCT00850343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: Subcutaneous (SC) injection
Study NCT00233987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 60 mg/kg IV over 4 hours 4 days before transplant.
Study NCT00233987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: 150 mg/m\^2 IV 1 day before transplant.
Study NCT00233987 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous-autologous tandem hematopoietic stem cell transplantation
Description: 2.0 x 10\^6 CD34+ cells, beginning at least 24 hours after melphalan infusion.
Study NCT00233987 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 150 centigray (cGy) total body irradiation given b.i.d on days 5-8 before transplant.
Study NCT02704195 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unilateral reduction of stimulation
Description: 30% unilateral reduction of Subthalamic nucleus stimulation
Study NCT02704195 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chronic Subthalamic nucleus stimulation
Description: This arm is the reference, with the best stimulation parameters
Study NCT01959490 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV
Study NCT01959490 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Given IV
Study NCT01959490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study NCT01959490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT01959490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Given IV
Study NCT01959490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT03463616 — intervention group
Intervention type: RADIATION
Intervention: CT abdomen
Description: CT scan of abdomen for metastasis staging of rectal cancer
Study NCT01959490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT01959490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT03691688 — intervention group
Intervention type: DRUG
Intervention: Aspirin 100 mg
Description: Aspirin 100mg will be prescribed for antiplatelet therapy at the physician's discretion
Study NCT03691688 — intervention group
Intervention type: DRUG
Intervention: Clopidogrel 75mg
Description: Clopidogrel will be prescribed for antiplatelet therapy in case of aspirin intolerance at the physician's discretion
Study NCT01834898 — intervention group
Intervention type: DRUG
Intervention: Controlled-release oxycodone
Description: Controlled-release oxycodone. First day postoperatively, 40 mg / day divided into 20 mg of 12 in 12 hours and in the second postoperative day, 20 mg / day divided into 10 mg of 12 in 12 hours
Study NCT06136897 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT06136897 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT06136897 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT06136897 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Given IV
Study NCT06136897 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiologic Examination
Description: Undergo radiologic evaluation
Study NCT06136897 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV
Study NCT05589025 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulpotomy technique with formocresol
Description: The pulpotomy procedure performed was a modification of that described by Pinkham et al; 2005 where pulp chamber was unroofed using a no. 330 sterile bur in a water-cooled high-speed handpiece. The entire roof of pulp chamber and overhanging dentinal remnants over the pulp horns were removed. After the completion of the access cavity, coronal pulp was extirpated using a sharp excavator. Any residual coronal pulpal tissue was removed using a sterile round bur in a slow-speed handpiece to a depth of few millimeters below the free gingival margin. Hemostasis was achieved with a water-dampened cotton pellet. If hemostasis was not achieved after the initial application of the cotton pellet, the case was eliminated from the study. Following hemostasis, a cotton pellet, moistened with formocresol was applied for 3 minutes and removed. A zinc- oxide and eugenol base was placed over the amputation site. Thereafter, a glass ionomer base was applied.
Study NCT03610789 — intervention group
Intervention type: DEVICE
Intervention: REDAPT
Description: REDAPT Monolithic Sleeveless Stems and Acetabular Cup Components
Study NCT03463616 — intervention group
Intervention type: RADIATION
Intervention: MRI abdomen
Description: MRI of abdomen for metastasis staging of rectal cancer
Study NCT05589025 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulpectomy technique with zinc oxide and eugenol
Description: The pulpectomy procedure used herein was a modification of that described by Payne et al;1993 Pulp chamber was unroofed using a no. 330 sterile bur in a water-cooled high-speed handpiece. The entire roof of pulp chamber and overhanging dentinal remnants over the pulp horns were removed. An initial endodontic K-file fitting snugly in the canal was introduced inside it. In most cases, the pulp tissue was removed completely on the first attempt. If the first attempt was unsuccessful, the procedure was repeated and canals were generally enlarged three sizes past the initial file to eliminate the organic remnants. Copious irrigation with a light flow of sterile 0.9% NaCl-solution was used throughout the procedure. At the end, the canals were dried and filled with zinc-oxide \& eugenol.
Study NCT03278522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramosetron
Description: Intravenous ramosetron 0.6mg is given to the patients at the induction of anesthesia, or at the end of surgery
Study NCT02023866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cysteamine Bitartrate
Description: Cysteamine Bitartrate Delayed-release capsules
Study NCT01142570 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caloric Support (Group 1)
Description: Four group 1-dose of caloric support will be calculated by Hariss-Benedict Formula measurement of Resting Energy Expenditure(REE).
Study NCT01142570 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caloric Support (Group 2)
Description: For group 2- dose of caloric support will be calculated by Indirect Calorimetric measurement of Resting Energy Expenditure(REE)
Study NCT01142570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein dose of 1.1 to 1.5 grams per kilogram weight.
Description: Patients in the first group(Group 1A) will receive caloric support calculated by the HARRISS BENEDICT equation and protein dose of 1.1 to 1.5 grams per kilogram weight.
Study NCT01142570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein at 1.1 grams per kilogram weight.
Description: Patients in the second group(Group 2A) will receive caloric support as measured by indirect calorimetry and will receive protein at 1.1 grams per kilogram weight.
Study NCT01142570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: protein at a dose of 1.5 grams per kilogram weight.
Description: Patients in the third group (Group 3A) will receive caloric support as measured by indirect calorimetry and will receive protein at a dose of 1.5 grams per kilogram weight.
Study NCT04234815 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CETA Short Session (CSS)
Description: CETA Short Session (CSS) is a brief, low-intensity psychosocial intervention incorporating foundational components of the Common Elements Treatment Approach (CETA). CETA is an 8-12 session, transdiagnostic psychotherapy for common mental disorders. CSS was designed to serve as both a prevention/support approach for a broader range of needs, as well as an engagement/outreach strategy to identify and refer individuals to treatment. CSS is delivered in a group format over approximately two hours and consists of: 1) Psychoeducation: instruction about the brain and brain functioning, including normalization of psychological responses to stress and a brief self-assessment; 2) Safety: screening and referral for individuals identified as at risk of harm to self or others; and 3) Cognitive coping: based on the cognitive triangle, participants practice identifying an unhelpful thought changing it to a more helpful alternative, and examining how these thoughts impact feelings and behaviors.
Study NCT04234815 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation and Safety
Description: This intervention is the same as CSS with the exception that the cognitive coping skill training is removed.
Study NCT03084575 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thermal radio Frequency, selective (unilateral S3, bilateral S4 and S5) saddle rhizotomy
Description: Thermal RF lesioning is done using Bailys RF generator. TRF parameters are 80 C, 120 seconds the TRF lesion is repeated after 180 rotation of the needle tip again after sensory and motor pre-stimulation.
Study NCT03084575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyperbaric chemical saddle Rhizotomy (6 % pherol in glycerin)
Description: L5-S1 intrathecal injection of 0.5-1 ml of 6 % pherol in glycerin. The patient is seated in the sitting position with 30-45o leaning backwards to make the posterior sensory roots lowermost.
Study NCT03084575 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermal RF lesioning is done using Bailys RF generator
Study NCT00718419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzastaurin
Description: Enzastaurin: Cycle 1 Day 1 only: 3, 125-milligrams (mg) tablets three times on Day 1 (Day 1 total dose = 1125 mg)~Day 2 onwards and subsequent Cycles: 2, 125-mg tablets orally twice a day (500 mg total per day).~Cycle length (all cycles): 28 days. Patients may stay on drug past 8 cycles, (until the study is closed) or until disease progression.
Study NCT00861367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: transurethral surgery with or without aspirin
Description: aspirin 100mg once a day, transurethral surgery with or without aspirin
Study NCT00861367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: transurethral surgery with or without aspirin
Description: aspirin 100mg once a day, transurethral surgery with or without aspirin
Study NCT06365294 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rescue extracranial stenting
Description: Rescue extracranial stenting in tandem occlusions
Study NCT02397213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclosporin
Description: Single dose of CicloMulsion® 5 mg/ml, 2.5 mg/kg (=0.5 ml/kg) as intravenous injection preoperatively after anesthesia induction.
Study NCT02397213 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All components of the CicloMulsion® emulsion except ciclosporin: soybean oil (refined), triglycerides (medium-chain), egg lecithin, glycerol, oleic acid, sodium hydroxide and water for injection (=0.5 ml/kg).
Study NCT01523119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Orally Disintegrating Tablets 8 mg
Study NCT01523119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Orally Disintegrating Tablets 8 mg
Study NCT01902082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Study NCT01902082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04119726 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Text Messages
Description: Regular messages about prevention and cure of CHD will be sent to both groups four times a week. The short texts will be selected from the guidelines in China to avoid misinformation. There are also some pictures or videos that help patients change their behaviour.
Study NCT04119726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Text Messages
Description: Regular messages about prevention and cure of CHD will be sent to both groups four times a week. The short texts will be selected from the guidelines in China to avoid misinformation. There are also some pictures or videos that help patients change their behaviour.
Study NCT04119726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized reminders
Description: Personal information, life behavior and risk factors will be registered when patients are enrolled. According to the baseline information, personalized knowledge will be sent to patients in the intervention group. Besides, patients will receive drug information and regular medication adherence reminders daily according to patients' baseline prescription drugs and modifications.